^
    BIOMARKER:

    MET amplification + EGFR mutation

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Contact us to learn more about our Premium Content:
    News alerts, weekly reports and conference planners
    Entrez ID:
    1956; 4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    MET amplification + EGFR mutation
    Non Small Cell Lung Cancer
    osimertinib + tepotinib
    Sensitive
    :
    C3
    ESMO 2022 - 3 weeks - (New C3)
    MET amplification + EGFR mutation
    Non Small Cell Lung Cancer
    lazertinib + ABN401
    Sensitive
    :
    D
    ESMO 2022 - 3 weeks - (New D)
    MET amplification + EGFR mutation
    Non Small Cell Lung Cancer
    gefitinib + tepotinib
    Sensitive
    :
    C3
    MET amplification + EGFR mutation
    Non Small Cell Lung Cancer
    crizotinib
    Sensitive
    :
    C3
    MET amplification + EGFR mutation
    Non Small Cell Lung Cancer
    gefitinib + capmatinib
    Sensitive
    :
    C3
    MET amplification + EGFR mutation
    Non Small Cell Lung Cancer
    osimertinib + savolitinib
    Sensitive
    :
    C3
    MET amplification + EGFR mutation
    Non Small Cell Lung Cancer
    osimertinib
    Resistant
    :
    D